Zobrazeno 1 - 6
of 6
pro vyhledávání: '"S W, Kirsa"'
Publikováno v:
Internal Medicine Journal. 42:1224-1229
BACKGROUND: The off-label use of a drug refers to a use outside the terms of its approval by the Therapeutic Goods Administration (TGA). It is also possible to prescribe unlicensed drugs under the TGA's special access scheme. A high rate of off-label
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54c1f5517df820d66a033fabd1f57c6f
https://doi.org/10.1111/j.1445-5994.2012.02751.x
https://doi.org/10.1111/j.1445-5994.2012.02751.x
Autor:
C O, Morrissey, N M, Gilroy, N, Macesic, P, Walker, M, Ananda-Rajah, M, May, C H, Heath, A, Grigg, P G, Bardy, J, Kwan, S W, Kirsa, M, Slavin, T, Gottlieb, S, Chen
Publikováno v:
Internal medicine journal. 44(12b)
Invasive fungal disease (IFD) causes significant morbidity and mortality in patients undergoing allogeneic haemopoietic stem cell transplantation or chemotherapy for haematological malignancy. Much of these adverse outcomes are due to the limited abi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b6643413b8ab68ba70c020ccea0bb4e0
https://pubmed.ncbi.nlm.nih.gov/25482742
https://pubmed.ncbi.nlm.nih.gov/25482742
Publikováno v:
Internal medicine journal. 42(11)
The off-label use of a drug refers to a use outside the terms of its approval by the Therapeutic Goods Administration (TGA). It is also possible to prescribe unlicensed drugs under the TGA's special access scheme. A high rate of off-label prescribing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9f57b896accf99630dd6f04e1377abc9
https://pubmed.ncbi.nlm.nih.gov/22372936
https://pubmed.ncbi.nlm.nih.gov/22372936
Autor:
S, Lingaratnam, M A, Slavin, L, Mileshkin, B, Solomon, K, Burbury, J F, Seymour, R, Sharma, B, Koczwara, S W, Kirsa, I D, Davis, M, Prince, J, Szer, C, Underhill, O, Morrissey, K A, Thursky
Publikováno v:
Internal medicine journal. 41(1b)
An abundance of new evidence regarding treatment strategies for neutropenic fever is likely to contribute to variability in practice across institutions and clinicians alike.To describe current clinical practices in Australia, by surveying haematolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::576d48df205aee895df42f5de0dae650
https://pubmed.ncbi.nlm.nih.gov/21272175
https://pubmed.ncbi.nlm.nih.gov/21272175
Publikováno v:
Internal medicine journal. 41(1b)
Although the incidence of neutropenic fever (FN) is estimated to be up to 80% for some malignancies, the epidemiological characteristics and economic burden are not well understood for Australian patients.To describe underlying malignant conditions,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dc0d29010cad7ccc3e789ae320be7e4a
https://pubmed.ncbi.nlm.nih.gov/21272176
https://pubmed.ncbi.nlm.nih.gov/21272176
Autor:
S, Lingaratnam, M A, Slavin, B, Koczwara, J F, Seymour, J, Szer, C, Underhill, M, Prince, L, Mileshkin, M, O'Reilly, S W, Kirsa, C A, Bennett, I D, Davis, O, Morrissey, K A, Thursky
Publikováno v:
Internal medicine journal. 41(1b)
The current consensus guidelines were developed to standardize the clinical approach to the management of neutropenic fever in adult cancer patients throughout Australian treating centres. The three areas of clinical practice covered by the guideline
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::715edacf020a1ce5a4379d6e32155823
https://pubmed.ncbi.nlm.nih.gov/21272171
https://pubmed.ncbi.nlm.nih.gov/21272171